BLA 761062 · Amgen INC
Evenity
Romosozumab-Aqqg · Injection
NovelLast checked: Nov 20, 2026Latest source record: Dec 20, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Apr 9, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
45
11 Phase 3, 8 recruiting
FAERS reports
14,247
8,363 serious, 759 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE AND CARDIOVASCULAR DEATH EVENITY may increase the risk of myocardial infarction, stroke, and cardiovascular death [see Warnings and Precautions (5.1) ] . EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY should be discontinued. WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE AND CARDIOVASCULAR DEATH See full prescribing information for complete boxed warning. EVENITY may increase the risk of myocardial infarction, stroke and cardiovascular death. ( 5.1 ) EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year....
What it is approved for
From the label in effect Jul 16, 2026.
EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1 ) Limitations of Use: Limit duration of use to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered. ( 1.2 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. 1.2 Limitations of Use The anabolic effect of EVENITY wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered [see Dosage and Administration (2.2) and Clinical Studies (14.1) ] .
Mechanism: EVENITY inhibits the action of sclerostin, a regulatory factor in bone metabolism. EVENITY increases bone formation and, to a lesser extent, decreases bone resorption. Animal studies showed that romosozumab-aqqg stimulates new bone formation on trabecular and cortical bone surfaces by stimulating osteoblastic activity resulting in increases in trabecular and cortical bone mass and improvements in bone structure and strength [see Nonclinical Toxicology (13.2) and Clinical Studies (14.1) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 9, 2019 Original approval · Type 1 - New Molecular Entity NovelLabelMedication GuideLetter
1 products under this application
- EVENITY · ROMOSOZUMAB-AQQG 105MG/1.17ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Romosozumab" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01575834 · 7,180 participants · Start Mar 15, 2012 · Primary completion Dec 14, 2015
Drug: Romosozumab; Placebo and 1 more · For: Postmenopausal Osteoporosis
Sites: Tucson, Arizona; Laguna Hills, California; Los Angeles, California · 218 sites in all
- Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With OsteoporosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01631214 · 4,093 participants · Start May 4, 2012 · Primary completion Feb 27, 2017
Drug: Romosozumab; Alendronate and 2 more · For: Postmenopausal Women With Osteoporosis
Sites: Birmingham, Alabama; Peoria, Arizona; Phoenix, Arizona · 316 sites in all
- An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal WomenPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01796301 · 436 participants · Start Jan 31, 2013 · Primary completion May 14, 2015
Drug: Romozosumab; Teriparatide · For: Postmenopausal Osteoporosis
Sites: Gainesville, Georgia; Bethesda, Maryland; Boston, Massachusetts · 50 sites in all
- Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral DensityPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00896532 · 419 participants · Start Jun 3, 2009 · Primary completion Feb 21, 2011
Drug: Placebo to Romosozumab; Alendronate and 5 more · For: Low Bone Mineral Density; Postmenopausal Osteoporosis
- Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary NailingPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00907296 · 402 participants · Start Sep 2, 2009 · Primary completion Mar 6, 2012
Drug: Romosozumab; Placebo · For: Fracture Healing
Sites: Birmingham, Alabama; Orange, California; Aurora, Colorado · 103 sites in all
- Study To Assess FRacTure Healing With SclerosTin Antibody - HipPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01081678 · 332 participants · Start Jun 20, 2010 · Primary completion Jun 30, 2012
Drug: Placebo; Romosozumab · For: Fracture Healing
Sites: Birmingham, Alabama; Pomona, California; Aurora, Colorado · 99 sites in all
- A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With OsteoporosisPivotal-lookingCompleted
NCT05067335 · 327 participants · Start Oct 21, 2021 · Primary completion Nov 9, 2023
Drug: Romosozumab; Placebo · For: Osteoporosis
Sites: Beijing, China; Chengdu, China; Foshan, China · 30 sites in all
- Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC InjectionsPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07811999 · 308 participants (planned) · Start Sep 22, 2026 · Primary completion Jan 14, 2027
Drug: Romosozumab · For: Healthy Participants
Sites: Miami, Florida; Leeds, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fall844
- fracture676
- arthralgia670
- injection site pain592
- off label use528
- headache498
- hospitalisation481
- bone density abnormal463
- product storage error357
- pain344
- pain in extremity340
- spinal fracture335
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 776 |
| 2020 | 1,210 |
| 2021 | 1,454 |
| 2022 | 2,389 |
| 2023 | 2,110 |
| 2024 | 2,143 |
| 2025 | 2,097 |
| 2026 | 2,067 |
Recalls
1 FDA enforcement reports for this application.
Apr 21, 2025 · Class II · Ongoing
CGMP Deviations; potential temperature excursions due to transit delays
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Evenity (Romosozumab-Aqqg)
2024 spending
$1.4M
Beneficiaries
200
595 claims
Per beneficiary
$7,135
$1,026.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $73,487 |
| 2021 | $99,694 |
| 2022 | $363,407 |
| 2023 | $1,024,894 |
| 2024 | $1,427,075 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C, Kansagara D, Lazur B, et al. · Ann Intern Med 2023 · Systematic Review, Network Meta-Analysis
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
Händel MN, Cardoso I, von Bülow C, et al. · BMJ 2023 · Systematic Review, Network Meta-Analysis
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG, Petersen J, Brandi ML, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Cosman F, Crittenden DB, Adachi JD, et al. · N Engl J Med 2016 · Multicenter Study, Randomized Controlled Trial
- Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P, Kapoor E, Asi N, et al. · J Clin Endocrinol Metab 2019 · Research Support, Non-U.S. Gov't, Network Meta-Analysis
- 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial.
Leder BZ, Ramchand SK, Jordan M, et al. · Lancet Diabetes Endocrinol 2026 · Randomized Controlled Trial, Equivalence Trial
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.